Severe thrombocytopenia in refractory chronic immune thrombocytopenia purpura

Severe thrombocytopenia in refractory chronic immune thrombocytopenia purpura is a high-risk hematologic state marked by a profoundly depressed peripheral platelet count—typically defined as fewer than 20,000 to 30,000 platelets per microliter or accompanied by clinically significant bleeding It primarily affects the hematologic and immune systems of adults, characterized by autoimmune-mediated platelet clearance and impaired megakaryocyte thrombopoiesis that fail to achieve sustained hemostatic...

Severe thrombocytopenia in refractory chronic immune thrombocytopenia purpura is a high-risk hematologic state marked by a profoundly depressed peripheral platelet count—typically defined as fewer than 20,000 to 30,000 platelets per microliter or accompanied by clinically significant bleeding Pathophysiologically driven by persistent autoantibody production and cytotoxic T-cell dysregulation, this severe clinical stage places patients at heightened risk for recurrent mucocutaneous hemorrhage, pu...

Severe thrombocytopenia in refractory chronic immune thrombocytopenia purpura is a high-risk hematologic state marked by a profoundly depressed peripheral platelet count—typically defined as fewer than 20,000 to 30,000 platelets per microliter or accompanied by clinically significant bleeding—in patients with immune thrombocytopenia persisting beyond twelve months

It primarily affects the hematologic and immune systems of adults, characterized by autoimmune-mediated platelet clearance and impaired megakaryocyte thrombopoiesis that fail to achieve sustained hemostatic responses to standard therapies, including corticosteroids, intravenous immunoglobulins, thrombopoietin receptor agonists, or splenectomy Pathophysiologically driven by persistent autoantibody production and cytotoxic T-cell dysregulation, this severe clinical stage places patients at heighte...

It primarily affects the hematologic and immune systems of adults, characterized by autoimmune-mediated platelet clearance and impaired megakaryocyte thrombopoiesis that fail to achieve sustained hemostatic responses to standard therapies, including corticosteroids, intravenous immunoglobulins, thrombopoietin receptor agonists, or splenectomy

Pathophysiologically driven by persistent autoantibody production and cytotoxic T-cell dysregulation, this severe clinical stage places patients at heightened risk for recurrent mucocutaneous hemorrhage, purpura, and potentially life-threatening internal or intracranial bleeding